Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Clin Orthop Relat Res. 2024 Apr 1;482(4):702-712. doi: 10.1097/CORR.0000000000002874. Epub 2023 Oct 5.
Patients undergoing massive tumor resection and total femur replacement (TFR) face a substantial risk of hip dislocation and infection, often resulting in multiple implant revisions or hip disarticulation. These complications can impact their independence and prognosis. Additionally, their shorter life expectancy is influenced by challenges in achieving local radical resection and controlling metastases. Identifying suitable candidates for TFR is vital, necessitating investigations into dislocation, infection, implant failure rates, local recurrence, overall survival, and associated factors.
QUESTIONS/PURPOSES: (1) What is the postsurgical complication (hip dislocation and infection) rate and factors associated with postsurgical complications in patients who underwent TFR after tumor resection? (2) What is the local recurrence rate, implant failure rate, overall survival rate, and factors associated with local recurrence and implant failure?
We retrospectively evaluated 42 patients (median [range] age 47 years [10 to 79 years]) who underwent TFR and tumor resection at the time of the same surgical procedure between 1990 and 2020 at 12 registered institutions that specialized in tumor treatment in Japan. A total of 55% (23) of the patients were men, and 79% (33) had bone sarcoma. The median (range) follow-up period was 36.5 months (2 to 327 months). Of the 42 patients, 12% (5) were lost to follow-up before 2 years without meeting a study endpoint (postsurgical complications, revision, or amputation), and another 19% (8) died before 2 years with implants intact, leaving 69% (29) of the original group who had either follow-up of at least 2 years or met a study endpoint before the minimum surveillance duration. Another 10% (4) had a minimum of 2 years of follow-up but had not been seen in the past 5 years. Infection was defined as deep-seated infection involving soft tissues, bones, joints, and the area around the implant. We did not consider superficial infections. Implant failure was defined when a patient underwent reimplantation or amputation. The complication and implant failure rates were assessed by the cumulative incidence function method, considering competing events. The Kaplan-Meier method was used to estimate the overall survival rate.
The 1-month, 6-month, 1-year, and 2-year dislocation rates were 5%, 12%, 14%, and 14%, respectively. The 1-month, 6-month, 1-year, and 2-year infection rates were 5%, 7%, 10%, and 15%, respectively. Multivariable analyses for hip dislocation and infection revealed that resection of the abductor muscles and large tumor size were positively associated with hip dislocation. The 6-month, 1-year, and 2-year local recurrence rates were 5%, 15%, and 15%, respectively. The 6-month, 1-year, 2-year, and 5-year implant failure rates were 5% (95% confidence interval 1% to 15%), 7% (95% CI 2% to 18%), 16% (95% CI 6% to 29%), and 16% (95% CI 6% to 29%), respectively. Multivariable analyses of local recurrence and implant failure that led to reimplantation or amputation revealed that a positive surgical margin was positively associated with local recurrence. The 1-year, 2-year, and 5-year overall patient survival rates were 95% (95% CI 87% to 102%), 77% (95% CI 64% to 91%), and 64% (95% CI 48% to 81%), respectively.
Hip dislocation, infection, and local recurrence were frequently observed in patients who received massive tumor resection and TFR in our study, eventually leading to reimplantation or amputation. Preserving the abductor muscles and resecting the tumor with a wide margin can prevent postoperative dislocation and local recurrence. Future research should focus on patient selection criteria, prevention of hip dislocation, and innovative treatments.
Level IV, therapeutic study.
接受巨大肿瘤切除和全股骨置换(TFR)的患者面临髋关节脱位和感染的高风险,这通常导致多次植入物翻修或髋关节离断。这些并发症会影响他们的独立性和预后。此外,他们的预期寿命较短,这是由于实现局部根治性切除和控制转移的挑战所致。确定适合 TFR 的患者至关重要,需要研究脱位、感染、植入物失败率、局部复发、总生存率和相关因素。
问题/目的:(1)在接受肿瘤切除后接受 TFR 的患者中,手术后并发症(髋关节脱位和感染)的发生率以及与手术后并发症相关的因素是什么?(2)局部复发率、植入物失败率、总生存率以及与局部复发和植入物失败相关的因素是什么?
我们回顾性评估了 1990 年至 2020 年期间在日本 12 个专门从事肿瘤治疗的注册机构接受肿瘤切除同期 TFR 的 42 名患者(中位年龄 47 岁[10 至 79 岁])。共有 55%(23 名)的患者为男性,79%(33 名)为骨肉瘤患者。中位(范围)随访时间为 36.5 个月(2 至 327 个月)。在 42 名患者中,有 12%(5 名)在未达到 2 年的研究终点(手术后并发症、翻修或截肢)之前失访,另外 19%(8 名)在 2 年内因植入物完整而死亡,而原始组的 69%(29 名)有随访时间至少 2 年或在最短监测时间前达到研究终点。另外 10%(4 名)有至少 2 年的随访,但在过去 5 年内未就诊。感染定义为涉及软组织、骨骼、关节和植入物周围区域的深部感染。我们不考虑浅表感染。植入物失败定义为患者接受再植入或截肢。并发症和植入物失败率通过考虑竞争事件的累积发生率函数方法进行评估。使用 Kaplan-Meier 方法估计总生存率。
1 个月、6 个月、1 年和 2 年的脱位率分别为 5%、12%、14%和 14%。1 个月、6 个月、1 年和 2 年的感染率分别为 5%、7%、10%和 15%。髋关节脱位和感染的多变量分析显示,外展肌切除和肿瘤较大与髋关节脱位呈正相关。6 个月、1 年和 2 年的局部复发率分别为 5%、15%和 15%。6 个月、1 年、2 年和 5 年的植入物失败率分别为 5%(95%置信区间 1%至 15%)、7%(95%置信区间 2%至 18%)、16%(95%置信区间 6%至 29%)和 16%(95%置信区间 6%至 29%)。导致再植入或截肢的局部复发和植入物失败的多变量分析显示,阳性手术切缘与局部复发呈正相关。1 年、2 年和 5 年的总患者生存率分别为 95%(95%置信区间 87%至 102%)、77%(95%置信区间 64%至 91%)和 64%(95%置信区间 48%至 81%)。
在我们的研究中,接受巨大肿瘤切除和 TFR 的患者经常出现髋关节脱位、感染和局部复发,最终导致再植入或截肢。保留外展肌和广泛切除肿瘤可以预防术后脱位和局部复发。未来的研究应侧重于患者选择标准、预防髋关节脱位和创新治疗方法。
IV 级,治疗性研究。